NCT07277322 is a Phase 1, PHASE2 clinical trial of Dupilumab in Metastatic Colorectal Cancer, sponsored by Dan Feng.

Who is sponsoring NCT07277322?

NCT07277322 is sponsored by Dan Feng.

What drugs are being tested in NCT07277322?

Interventions in NCT07277322: Dupilumab, Toripalimab.

What condition does NCT07277322 study?

NCT07277322 studies Metastatic Colorectal Cancer, Liver Metastases.

Is NCT07277322 still recruiting?

NCT07277322 is currently not yet recruiting. Last updated 2 March 2026.

Last reviewed 2026-03-02 · How we verify

NCT07277322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Not yet recruiting Phase 1, PHASE2 Last updated 2 March 2026

What this trial tests

Phase 1, PHASE2 trial testing Dupilumab in Metastatic Colorectal Cancer in 24 participants. Not yet recruiting.

Timeline

15 March 2026

Primary endpoint
31 December 2028

31 December 2030

Quick facts

Lead sponsor	Dan Feng
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	15 March 2026
Primary completion	31 December 2028
Estimated completion	31 December 2030
Sites	1 location across United States

Drugs / interventions tested

Dupilumab (DUPILUMAB) — full drug profile →
Toripalimab (TORIPALIMAB) — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Liver Metastases — all drugs for Liver Metastases →

Sponsor

Dan Feng

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dupilumab

Trials testing the same drug.

NCT07316114 — A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spont · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07399067 — A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07330934 — A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Dan Feng trials

Trials by the same sponsor.

NCT07281716 — Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07277322 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dan Feng
Last refreshed: 2 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07277322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing